CREDIT: New York Genome Center
Researchers at the New York Genome Center (NYGC) and Columbia University have uncovered a molecular mechanism behind one of biology's long-standing mysteries: why individuals carrying identical gene mutations for a disease end up having varying severity or symptoms of the disease. In this widely acknowledged but not well understood phenomenon, called variable penetrance, the severity of the effect of disease-causing variants differs among individuals who carry them.
Reporting in the August 20 issue of Nature Genetics, the researchers provide evidence for modified penetrance, in which genetic variants that regulate gene activity modify the disease risk caused by protein-coding gene variants. The study links modified penetrance to specific diseases at the genome-wide level, which has exciting implications for future prediction of the severity of serious diseases such as cancer and autism spectrum disorder.
NYGC Core Faculty Member and Columbia University Department of Systems Biology Assistant Professor Dr. Tuuli Lappalainen led the study alongside post-doctoral research fellow Dr. Stephane Castel.
"Our findings suggest that a person's disease risk is potentially determined by a combination of their regulatory and coding variants, and not just one or the other," Dr. Lappalainen said. "Most previous studies have focused on either looking for coding variants or regulatory variants that affect disease in these individuals or potentially looking at common variants that could affect disease. We have merged these two fields into one clear hypothesis that uses data from both of them, which was fairly unheard of before."
Variable penetrance has long posed a challenge for predicting the severity of a disease, even for diseases with a strong genetic association. Dr. Lappalainen and colleagues developed the modified penetrance hypothesis from their interest in the idea that gene variants that regulate the activation of genes could also play a role in modifying the penetrance of coding variants for the same gene.
As a first test of the modified penetrance hypothesis, the researchers conducted an analysis of data from the Genotype-Tissue Expression (GTEx) project, a large catalog of genetic variants that affect gene expression in humans, to evaluate the interactions of regulatory and coding variants in a human population without severe genetic diseases. They found an enrichment of combinations of regulatory and coding variants, called haplotypes, that act as protective against disease by decreasing the penetrance of coding variants associated with disease development. This finding was expected in the general population, Dr. Castel explained, as a result of natural selection removing damaging gene variants from the genome over time.
To test their hypothesis in a disease-specific population of patients, the researchers analyzed data from the National Institutes of Health's The Cancer Genome Atlas (TCGA) and the Simons Simplex Collection, a permanent repository of genetic samples from 2,600 families, each of which has one child affected with an autism spectrum disorder, and unaffected parents and siblings. In the cancer patients and individuals with autism, they found an enrichment of haplotypes predicted to increase the penetrance of coding variants associated with cancer and autism spectrum disorder, respectively.
Finally, they designed an experiment using CRISPR/Cas9 genome editing technology to test the modified penetrance hypothesis with a coding variant that is known to be associated with a disease. They chose a coding variant associated with Birt-Hogg-Dubé Syndrome, a rare hereditary disease that increases the risk of certain types of tumors. They edited the SNP into a cell line on different haplotypes with a regulatory variant. The researchers were able to show that the regulatory variant indeed modified the effect of the coding disease-causing variant, consistent with expectations based on the large-scale data collections. This finding provides an important framework for scientists moving forward to experimentally test specific disease SNPs to determine if they could be affected by modified penetrance.
"Now that we have demonstrated a mechanism for modified penetrance, the long-term goal of the research is better prediction of whether an individual is going to have a disease using their genetic data by integrating the regulatory and coding variants," Dr. Lappalainen said.
"In future, studies of the genetic causes of severe diseases should take into account this idea that regulatory variants need to be considered alongside coding variants," Dr. Castel said. "This should eventually lead to a more fine-grained understanding of the risk of coding variants associated with disease."